IGM Biosciences Inc (NASDAQ:IGMS)’s traded shares stood at 2.79 million during the last session, with the company’s beta value hitting 0.17. At the close of trading, the stock’s price was $2.00, to imply an increase of 16.96% or $0.29 in intraday trading. The IGMS share’s 52-week high remains $22.50, putting it -1025.0% down since that peak but still an impressive 17.5% since price per share fell to its 52-week low of $1.65. The company has a valuation of $118.92M, with an average of 1.01 million shares in intraday trading volume over the past 10 days and average of 355.50K shares over the past 3 months.
Analysts have given a consensus recommendation of Hold for IGM Biosciences Inc (IGMS), translating to a mean rating of 3.20. Of 1 analyst(s) looking at the stock, 0 analyst(s) give IGMS a Sell rating. 0 of those analysts rate the stock as Overweight while 1 advise Hold as 0 recommend it as a Buy. 0 analyst(s) have given it an Underweight rating. Estimates put the company’s current-quarter earnings per share at -0.77.
IGM Biosciences Inc (NASDAQ:IGMS) trade information
After registering a 16.96% upside in the last session, IGM Biosciences Inc (IGMS) has traded red over the past five days. The 5-day price performance for the stock is -70.59%, and -75.67% over 30 days. With these gigs, the year-to-date price performance is -67.27%. Short interest in IGM Biosciences Inc (NASDAQ:IGMS) saw shorts transact 2.51 million shares and set a 10.72 days time to cover.
The extremes give us $1.5 and $25 for target low and target high price respectively. As such, IGMS has been trading -1150.0% off suggested target high and 25.0% from its likely low.
IGM Biosciences Inc (IGMS) estimates and forecasts
Looking at statistics comparing IGM Biosciences Inc share performance against respective industry, we note that the company has outperformed competitors. IGM Biosciences Inc (IGMS) shares are -82.91% down over the last 6 months, with its year-to-date growth rate higher than industry average at 28.66% against 16.70%. The rating firms project that company’s revenue will grow 23.34% compared to the previous financial year.
Revenue forecast for the current quarter as set by 9 analysts is 366.67k. Meanwhile, for the current quarter, a total of 3 analyst(s) estimate revenue growth to 2.49M.Earnings reports from the last fiscal year show that sales brought in 651k and 497k respectively in the corresponding quarters. In this case, analysts estimate current quarter sales to fall -43.68% before jumping 400.47% in the following quarter.
IGMS Dividends
IGM Biosciences Inc has its next earnings report out in February. However, it is important to take into account that this dividend yield ratio is just an indicator to only serve the purpose of guidance. Investors interested to invest in the stock should ponder company’s other fundamental and operations related aspects too.
IGM Biosciences Inc (NASDAQ:IGMS)’s Major holders
IGM Biosciences Inc insiders hold 34.95% of total outstanding shares, with institutional holders owning 64.03% of the shares at 98.42% float percentage. In total, 64.03% institutions holds shares in the company, led by BAKER BROS. ADVISORS LP. As of 2024-06-30, the company held over 4.09 million shares (or 6.8042% of shares), all amounting to roughly $28.1 million.
The next major institution holding the largest number of shares is PRICE T ROWE ASSOCIATES INC /MD/ with 4.08 million shares, or about 6.7789% of shares outstanding. As of the market price on 2024-06-30, these shares were worth $28.0 million.
We also have Price (T.Rowe) New Horizons Fund and Price (T.Rowe) Health Sciences Fund as the top two Mutual Funds with the largest holdings of the IGM Biosciences Inc (IGMS) shares. Going by data provided on Sep 30, 2024 , Price (T.Rowe) New Horizons Fund holds roughly 1.97 shares. This is just over 5.77% of the total shares, with a market valuation of $3.93 million. Data from the same date shows that the other fund manager holds a little less at 849.75, or 2.49% of the shares, all valued at about 1.7 million.
